Discover how cutting-edge research on hyaluronic acid modified nanocarriers is revolutionizing the aerosolized delivery of verteporfin, offering new hope in the treatment of acute lung injury.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Hyaluronic acid modified nanocarriers for aerosolized delivery of verteporfin in the treatment of acute lung injury.
Cen et al., Int J Biol Macromol 2024
<!– DOI: 10.1016/j.ijbiomac.2024.131386 //–>
https://doi.org/10.1016/j.ijbiomac.2024.131386
This study explores the enhancement of Verteporfin (VER), a photosensitizer for macular degeneration, for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) through a novel delivery method. The hydrophobicity and limited bioavailability of VER are addressed by synthesizing HA@PLGA-VER (PHV) nanoparticles, combining hydrophilic hyaluronic acid (HA) with an oil-in-water system of a poly(lactic acid-co-glycolic acid) (PLGA) copolymer. The PHV nanoparticles, with an average size of approximately 200 nm, exhibit improved surface characteristics, bioavailability, and targeting ability. In vitro and in vivo studies confirm the biocompatibility, safety, and anti-inflammatory efficacy of PHV, showing suppression of M1 macrophage polarization and induction of M2 polarization. Aerosolized PHV treatment significantly enhances drug accumulation in the lungs, improves pulmonary function, reduces lung injury, and decreases mortality in ALI mice. This research underscores the potential of nebulized PHV as an effective delivery system for VER in ALI/ARDS treatment, offering a promising approach to improve therapeutic outcomes.